Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2014 Oct;34(10):2182-3.
doi: 10.1161/ATVBAHA.114.304486.

Rising like the phoenix?

Edward F Plow  1 , Mitali Das  2
Affiliations
Editorial

Rising like the phoenix?

Edward F Plow et al. Arterioscler Thromb Vasc Biol. 2014 Oct.
No abstract available

Keywords: platelet; platelet aggregation; thrombosis; αIIbβ3; αIIbβ3 antagonist.

PubMed Disclaimer

Conflict of interest statement

Disclosures

The authors report no conflicts.

Figures

Figure 1
Figure 1
Mechanism of action of RUC-4. (A) Ligands bind near MIDAS in the β integrin subunit leading to activation of resting integrins. (B) Unlike conventional αIIbβ3 integrin antagonists, RUC-4 displaces Mg2+ to bind at MIDAS. As no conformational change ensues, integrins cannot bind ligands and thus remain inhibited.
See this image and copyright information in PMC

Comment on

References

    1. Bledzka K, Smyth SS, Plow EF. Integrin aIIbB3: From Discovery to Efficacious Therapeutic Target. Circ.Res. 2013;112:1189–1200. - PMC - PubMed
    1. Coller BS. Translating from the rivers of Babylon to the coronary bloodstream. J.Clin.Invest. 2012;122:4293–4299. - PMC - PubMed
    1. Bosch X, Marrugat J, Sanchis J. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. Cochrane.Database.Syst.Rev. 2010 CD002130. - PubMed
    1. Cox D. Oral GPIIb/IIIa antagonists: what went wrong? Curr.Pharm.Des. 2004;10:1587–1596. - PubMed
    1. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists - A meta-analysis of phase III multicenter randomized trials. Circulation. 2001;103:201–206. - PubMed

MeSH terms